<SEC-DOCUMENT>0001193125-14-084235.txt : 20140305
<SEC-HEADER>0001193125-14-084235.hdr.sgml : 20140305
<ACCEPTANCE-DATETIME>20140305143037
ACCESSION NUMBER:		0001193125-14-084235
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140305
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140305
DATE AS OF CHANGE:		20140305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		14668638

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d686210d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;5, 2014 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Heron
Therapeutics, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-33221</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94-2875566</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>123 Saginaw Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Redwood City, CA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>94063</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (650)&nbsp;366-2626 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see</I> General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;5, 2014, Heron Therapeutics, Inc. (the
&#147;Company&#148;) issued a press release announcing its financial results for the quarter and year ended December&nbsp;31, 2013 (the &#147;Earnings Press Release&#148;). A copy of the Earnings Press Release is furnished as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The information set forth in this Item 2.02 and in Exhibit 99.1 shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities
Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. </I></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman">Document</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated March 5, 2014</TD></TR>
</TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">HERON THERAPEUTICS, INC.</TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;5, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian G. Drazba</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vice President, Chief
Financial Officer</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d686210dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g686210g83d48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Immediate Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Heron Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Corporate Progress </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REDWOOD CITY, Calif. &#150; March&nbsp;5, 2014 &#150; Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today reported fourth
quarter and full year 2013 financial results and highlighted recent corporate progress. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In the last 12 months, we transformed ourselves into Heron
Therapeutics and made important advancements to position Heron for success in 2014,&#148; said Barry D. Quart, PharmD, Chief Executive Officer of Heron Therapeutics. &#147;In 2013, we brought in a fresh and highly seasoned management team that is
focused on three key initiatives for 2014. Most importantly, we&#146;re concentrating on the resubmission of our New Drug Application for our lead product candidate, Sustol&#153;, for the treatment of chemotherapy induced nausea and vomiting (CINV).
Second, we initiated a Phase 3 program which, if successful, would allow us to demonstrate the benefit of Sustol in the treatment of delayed onset CINV in patients receiving highly emetogenic chemotherapy agents. This would represent a new medical
and market opportunity, as no 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB> antagonist is currently approved for this indication. And third, we plan to initiate clinical studies later this year for a new investigational product
targeting the relief of post-surgical pain using our proprietary Biochronomer&#153; drug delivery technology.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We believe that Heron
Therapeutics is in a strong position coming into 2014 and look forward to providing updates on our continued progress throughout the year,&#148; Dr.&nbsp;Quart continued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Heron Recent Highlights </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On January&nbsp;23, 2014, Heron Therapeutics announced that its common stock had been relisted on the NASDAQ Capital Market, trading under the symbol HRTX. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On January&nbsp;13, 2014, the Company announced that it had changed its name from A.P. Pharma, Inc. to Heron Therapeutics, Inc. and effected a 1-for-20 reverse stock split to increase the Company&#146;s stock price in
support of the Company&#146;s application to list on the NASDAQ Capital Market. The Company also announced the appointment of three new independent members to its board of directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- <I>more</I> - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B></B><I>Heron Therapeutics Announces Fourth Quarter and Full Year 2013</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Financial Results and Highlights Recent Corporate Progress</I></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> Page
 2
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On November&nbsp;25, 2013, the Company announced the closing of an underwritten public offering of 7.5&nbsp;million shares (as adjusted, post-reverse split) of common stock at a public offering price of $8.00 per share
(as adjusted, post-reverse split), which resulted in net proceeds of $57.8 million. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On November&nbsp;12, 2013, the Company announced the expansion of its pipeline to include a new program targeting the relief of post-surgical pain with the expected initiation of human clinical studies in mid-2014. The
Company also announced plans to pursue a post-approval expansion of the intended Sustol labeling by conducting a clinical study of Sustol for the treatment of delayed onset CINV in patients receiving highly emetogenic chemotherapy agents.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron
Therapeutics&#146; net loss for the fourth quarter of 2013 was $14.0 million, or $0.75 per share, compared to a net loss of $7.7 million, or $0.51 per share, for the fourth quarter of 2012. Net loss was higher in the 2013 quarter primarily due to
increased spending related to manufacturing development expenses and higher personnel costs, including stock compensation expense. Net loss for the fiscal year 2013 was $55.3 million, or $3.42 per share, compared with a net loss of $23.3 million, or
$1.91 per share, for 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents as of December&nbsp;31, 2013 were $72.3 million, compared to $53.5 million at December&nbsp;31,
2012. As noted above, Heron closed an underwritten public offering of 7.5&nbsp;million shares of common stock at an offering price of $8.00 per share and received net proceeds of $57.8 million from the offering. Net cash used in operating activities
was $40.8 million for the year ended December&nbsp;31, 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Sustol </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron&#146;s lead product candidate, Sustol&#153; (formerly known as APF530), is being developed for the prevention of both acute- and delayed-onset
chemotherapy-induced nausea and vomiting (CINV). One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT<SUB
STYLE="font-size:85%; vertical-align:bottom">3</SUB> antagonist approved for the prevention of delayed-onset CINV in patients receiving moderately emetogenic chemotherapy (MEC); none are approved for delayed-onset CINV in patients receiving highly
emetogenic chemotherapy (HEC). Sustol contains the 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB> antagonist granisetron formulated in the Company&#146;s proprietary Biochronomer&#153; drug delivery system, which allows therapeutic
drug levels to be maintained for five days with a single subcutaneous injection. Currently available intravenous and oral formulations of granisetron are approved only for the prevention of acute-onset CINV. Granisetron was selected for Sustol
because it is widely prescribed by physicians based on a well-established record of safety and efficacy. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B></B><I>Heron Therapeutics Announces Fourth Quarter and Full Year 2013</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Financial Results and Highlights Recent Corporate Progress</I></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> Page
 3
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Heron Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) is a specialty pharmaceutical company developing products using its proprietary Biochronomer&#153;
polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be
injected only once every one or two weeks. The Company&#146;s lead product, Sustol (formerly known as APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to Sustol, Heron is also utilizing its proprietary, sustained-release Biochronomer&#153; technology to develop other drugs designed to extend the
duration of action of known active ingredients to address important unmet medical needs. In November 2013, the Company announced movement into full development of the first of these new drug programs&#151;the Biochronomer extended release of an
established local anesthetic for the treatment of post-surgical pain. In recently completed, post-surgical animal models of pain, the Company&#146;s drug candidates demonstrated statistically significant pain relief for five days, representing the
potential to significantly reduce the need for opiates post-surgery and the length of post-surgical hospital stays. Heron expects to move its pain program into human clinical studies in mid-2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(financial tables follow) </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B></B><I>Heron Therapeutics Announces Fourth Quarter and Full Year 2013</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Financial Results and Highlights Recent Corporate Progress</I></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> Page
 4
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Heron Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three Months Ended<BR>December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended<BR>December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54,457</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from continuing operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,430</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from discontinued operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(55,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from continuing operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used to compute basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B></B><I>Heron Therapeutics Announces Fourth Quarter and Full Year 2013</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Financial Results and Highlights Recent Corporate Progress</I></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> Page
 5
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Heron Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable to related parties, net of discount</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(238,870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(183,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release contains &#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking
statements involve risks and uncertainties, including uncertainties associated with the potential approval of Sustol (formerly APF530) and the potential timing for such approval, if approved at all, as well as risks and benefits relating to listing
on the NASDAQ Capital Market, progress in research and development programs, launch and acceptance of new products and other risks and uncertainties identified in the Company&#146;s filings with the Securities and Exchange Commission. We caution
investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B></B><I>Heron Therapeutics Announces Fourth Quarter and Full Year 2013</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Financial Results and Highlights Recent Corporate Progress</I></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> Page
 6
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations Contacts: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Rice, 646-597-6979
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>mrice@lifesciadvisors.com </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Capuzelo,
858-703-6063 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jcapuzelo@herontx.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen R. Davis, 650-366-2626 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President and
Chief Operating Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>### </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g686210g83d48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686210g83d48.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`#4``0`!!0$!```````````````&`0($!0<#"`$!``(#`0$`
M``````````````$#`@0%!@?_P@`1"`!D`.0#`1$``A$!`Q$!_]H`#`,!``(0
M`Q````'[^`````````!0021"9\9BR8RL<@`````````!2'G,71/-.II\&[VC
MT'0ND>M9V/C=```````````4B('OZ^KNJC&U7\!?1?*??/SOU?4.7LT3+=38
M``````````I"V(Y!7POG3V'+X!['F]M\)O\`VCY'T4MW>G60`````````%(C
M785<$\[X?A5?C=3[[IRKYS3]-=WWW5.KZ4><XX-E>PINJ#4WZVFV-?!NJ`1C
ML*MC7W4BH3-.9T;4Q+H<[*PSE.CT-3=K[&FV%;'&^-?J'RW[Q^0_9:[F6WIV
M!KK,.&>@YTZYFVD.:=?0LG"2ZMP%)F'[NO,=&^I:C$SQTET3'3RG_/VL&S#G
M_0JUUN$BU[)GS=W$V.7/.5VN-=WG=HX?2&IMPXSVM3K?'VDAP3T&AGU9=LX>
MZD*(X?V]/N'$W>2]C5T]M7<N#O\`$NYI?1OF^C=*V&BNK^)?=<;[S^?]WG?2
MHA.[J]VX._P?T.E]!>>WQJ;L.5]34[1Q-ZH/F_TO-C.S5T'G[!(MF(WLU?3/
MENI644VZN(=W0G_/V.?[^O*M6S%S1N^JZ9^F?,]/UQG6VX<&[_/PLWTSYGIB
MV(U55&3.>;;;CX88.-?GG'EBSK;;8C%QKR<<[L,??//*LLU]-/A..?E;I<*-
MG9?BT4;+9V,B,JRH4AY3'ND6Q$#Y?)NF<RRR"<KDR3=W=;31B889F>?FA#)S
ML\8P]F72.UW('R>3=DB7/YW4^YWX!R^/L;;Y=T.EO=K;N```,.NM$95MFGU=
M75TT;6_8SK;L2NOVRRJC)LMBNCS]E=?B85R/;W<?'#QPPU=-.QMNUU5$BV]W
MUF:S(`````````````````#_Q``K$``"`@,``0,"!04!```````#!`(%``$&
M%1`1%A-`!Q07,302("$P,E#_V@`(`0$``04"^YF08HC,$VOM_?6O3J.AUSB`
M?Q1),WX@2<8H^'J25-']OT%1*YK^7A>+*?B&O];GE]Z@:F[NOMK&XL)UB-*:
MQ81^V_;.GM#++4_6..Q<A$3/#%6K"53Q;`/V[&]Z#9U3^D?RT]Y.F39Q-,\C
M5Z#"+7I*6H16:"V/U8>65FQ>U:AODU+GR:ESY-2Y\FI<)>5@A?)J7/DU+GR:
MESY-2X,L"P(88=3Z.F'(%[4L9J6I:;?41R,AEA942;256NZ6V"DJ":[B[,_1
MO^)SU_5H(_+*//EE'GRRCRXMD+*TF>H!TWD.-SR/&YY'C<\AQN6=E1'?\CQN
M>0XW/(\;C%AQOT:RU)34RW.&?P5)5`BSSU.SC*EGS>NA:5M`3K[*BE6725K"
MGJ15I<YCV\CZ/?X1XQ11NH\56YXJMSQ5;G5A`G<U@PM=IXJMSQ5;GBJW/%UN
M7ZRH>B\779<\:.9*R\K/S$:VMUE\6"?7>MD80$!E/JEC_P`V_.+V&UND?IS"
M(,T..)N=MZ/_`,'A-2C2>O:1GNZU<`H^R_4"HS]0*C/U`J,_4"HRR<A9WGI;
M4M?<@]N@XS;`:GM*H+_6\U@>^JIX7O5-[G6=)UL^T3@K&'_&-)K.A)2W/,EX
M`I&7/3?M[:83'FF5Y>FS"CJ1TI9/:.>]9FP*QU`*9([\=K<)*2S\VKFC@WZ;
M86]H&1AFB#EDV:R4H;6B/5@EO>XPG_;&$8[]/WU:*K:C;`$)*)+CV/\`5VG!
M=SZ;L"Z>LAM:6L6M2RL:@FXB(DC318C*O`UM)R$@[)*,1TRX25E(LO)<FY0$
M-)'Z1AHR@0#`P5Q`E3_T%`(V&`(\/VPE>H6'@ZW!H*BV8(SC6263QA4#40+`
M6R8XDAJBK(Y&M3@#PU?_`$Q'"$`+A6C%):&O#U^M?D5/H>'K_:`X#C_X@/_$
M`$80``(!`P$%`P@'!00+`0````$"`P`$$2$%$A,Q010541`B,E)A<8&2(T!"
M4U21L3.AP=/Q("1$T3`T4&)C<G."LM+PE/_:``@!`P`!/P'ZR2%](X'MH,K>
MBP/N/UCT>M:Z9J\NNS1JX7>);&*&TY&95X6,^VMI-(UNJ*A._J<:XK9T/!@R
M00S\^GUBZM^.FA(<<M:LEN8T:.?7<Y/X_P!*VHF]`#RW#FNVQ\5%P=X-TJ"_
MCDD6!01II5S,8(BZH9'Y*H\:MFF>,-.NXYZ>'U?EKG`K:>T^SN(-UTWAE9%]
M$_TH;:'!*RL9XG!&=-X'_.K5;9Y.*JL,:G/2K?:EM:2NY0RN-!CI[ZV;>RWL
M;220\$9\S/-AXX^K\JN/-A<A#+IJ@/.K[9M^+22XAG=K?7$#^G&??X"I.\"L
M4J(H>,X(SYO_`#8JSVF(K8[JB:^ETW%Y"HA?W-XMM%%N*/2\=_KGV"K"RGL;
MB'CF2[E=?2!Q'$OACKCIY6(12QT"C)]PJ">.X3?B;*\ORK]WEFNH(&CCD?=>
M4X6IMJV,$C12SA'3F*[[V;^(%=][-_$"N^]F_B!7?VS!_B.7LIMJ6*)'(TX5
M9/1H;;V:<@7`TKOO9OX@5WWLW\0*[ZV;I_>!K4;K*JO&X9#U%.Z1@EV"*.I.
M*DVSLV([K7*Y'AK4.U;"8X2Y3/M.[^M9&`1J*N;JWM-PSON;QP,T"DJY4AT;
MXBMI[#L[RRF@C1;9R,K(HP0?AX]:V;LR23:<"6Y)DA;4CT<!N9J&UMH7WXXD
M6;[3`:FH;J&=I$B;+0G=8>'ED&8W'/*G]*LVAMH>'RU)_?7:(1]K-=IA\:[3
M#XU=I'<36KJ0>$WA1M+/MMS--&KE\:$9Z5V;9?W"?+79ME_<)\M=FV7]PGRU
MP-F#_#Q^'HBKF"SDEMTW%W(^F-*[/LL<H$^6NS;+^X3Y:-OLH:<"/Y::VV7P
MS_=TR>7FU;![.W*+JSMYB^`KNWCG?NW+Y^QTI-G6,?*UC]Y4$_OJ39=A-SMD
M!\0,&A;SV6MNW$B7FC?P]U7T,5X+5I!E=[44MK)9$FV.8NJ'I[J22-QCT2W0
MULK9B[/DOG$802RDQ^(C_K6,<A5C`(9;ML`<1\Z>60XC<CHI_2K-`\667J:X
M4?J#\JX4?J"N%'Z@JYW8IK<*N-XU'NO=W"D>CBN%'Z@KA1^H*X4?J"N''KY@
MJ<HEQ`-SGI7"C`]`5+:Y\Z'S7'3QJ*XCWN%<1"*0=2-/SK<3[*+[ZG81W4.\
M/-Y>[R\JD\R-RQZ&@S+!!O=9-/)+!O@E3NOT-+=20L([I-T=''(T"K`%3D59
ML3)<@]'\L@S&X\5/Z58[XA.>C'']B\_UBTTS@T)5@O+EFS@@5WA#X-^1KO"'
MP;\C7>$/@WY&N\8!H0P^!J1N--;.@.`W45_#R2PQS#==<_PK%Q9G3Z6#V\Q1
M$=[%@>:1R\12275MYCQ[\:]>M#:$/)E9?@:-^O*.)Y"/97#N;L@R_11>KUJ\
MB([,B#2,YH<AY&177=89!K@2VIWX3OQ^J:V>69KEF7=R_7R^_04)[9!N\:,:
M^L/\ZXT)Y2K\P\ADC7.74!>>HTKM%OSXT>1_O"B]N`KNZ>?R.1K7&M<@<6/)
M]JT0@&3@`==,4O#<;R;K*>HP11EM<X,D>1[5TI9(G]%T81ZZ$:?ERKM-O]^G
MS"A+$<8D4YT&H\G'@`P94U\6%":V^S*@]S"@Z$'##"\SD:5VJTS^U33W4KQ;
MAD5EW/6&,?G0O;7...FOM%8!P=#X5R_L`*.0Y^7V5M""!1!B)!F9<^:-:VA`
ML=HS0QHC@KTQUH/M'`^@CZ?:J593;7IE53(9$T!TYTL5T$3%C;MD#F15TC]L
MLU2WC>18S]&3A!KTJ]CGX!W["*%<KET8%U&>F`*O;C*P6D7$EB`4S%%RV[T'
M_=UJQN%MKLVHBEBMIOV1D7=W6ZK5K&YEO-RUBG42\V(!SX4UI,&N)V1;9>$5
MW8SZ6G7%6<-QV6+%E`X*C!)&<>WVU<*8C9<:-8,2CT.7QIRJHS%@`!SZ<JV;
M#&]@K21*Q\\@D9TR>M;*@@,+GA+^U;&G*F;<CNQJB&Y`?'J9UI+:S$:\.)#'
MC0X'_P`:E2UW;B""9XQOC3'T>?5'LJ2&:.(AMGP21A=2I"G'4@>/NJQ:.2UC
M,(81XTWN8_T,D22[O$7.X<CGH?A4D,<J[LBY7PR1R]QK^%/96TBR(\>5E.6\
M]QDCVA@1\,5W38^I)_\`HN/YM)9V\;1LJ'>B&%)=R0/BQS\<U)%'*ACD&5;F
M,D?H0:@M8+;>X*;F]S\YF_\`(FIH(IU"RKO!2&&I&".6JD&HK>&`N8DW.(<M
MJ3D_$G'PID5E*L,J1@T-DV(&!&X'_7G_`)M"QMEB,.X3&>C/(Q^9F+#X&N[+
M/=W.&V[X<6;^9^ZE1401J,(-,5%#'""(EW0QR=2=?B32VL"<0"/24Y;))R?B
M3CX8KNVS`P(V`\.++_[Z5V2WX1@X8X9Z:Y^;.]GVYS7=MIC&X^!_QIOYE*JH
MH11NJ.0KE_L0_\0`2!```@$"`P0#"PD%!@<``````0(#``0%$2$2$S%!%%%A
M$!4B(S)3<8&2H;$&0$)25&*1P=$6)#-#TB!R<[+3X3!08X*3H_#_V@`(`0(`
M`3\!^:\.Y^7<56<[*`L>H:GW4R/&=ET9#U,"/C\XR/+E6=85AW?*X,6WNPB[
M1--\E45)'%SGL@GAU"ODX(8;XRR2I'N`0-LY`YZ<^=8]=B]OW96S1`%4CL^<
M8?>]"G$FPLJ'1@1GI6*M82RK/8#920>$GU6Y_C7R<EW>(J/K@K3P.(YE!U96
MR]8J\P&XM+9KIY`=D^$O8>!JQMENKA8GE$,?%G/T0*ODMHKAX[23>Q)IM=?S
M;W5F.JHL4LK"^A%_"7MW(4D<->?JK'X;?";&VQG#8]$=6.R<\HSS-6%V;W#[
M2\!S$\8/KKY:_*&&P*8<<VEV=XX7J^B#5C<M<Q;TH8@WD@Z$BA\W?/8.RNUV
M?I5Y:3-;F5`6C!SW9\I0.-17]W<6<MFMW/+9$`&,:@=A'$?"H<?Q_!,*L(KC
M"E2!%V()FUV@!F"X'.KF:7$[Z2XG\=?3MGLCR4'++L%0020S(9"TKE<ONH.Z
M`6(4:DG(5-!+;ONY5V6X^K^Q#;33+(T:[2Q#-NRH<-OIHTECA+(_DY5WFQ'[
M.:[S8C]G-=YL1^SFN\V)9Y&U(I,-OI'>-8"6CX]E=YL2'&"N\V(_9S7>;$?L
MYKO+B7V<Z4Z/$661=AEY'E2))(=F-2Y^Z"?A4>$XA(,UMGR]&52X;?0^7;/E
MV*3\*\DY'0CD1E5O;3W.WN$+[''*G1HR49"&'%2*PIX,,N1*ELC(_@NF0\('
M_>L3ELUPUFO(5>+=YHC>4&(T"CEE2V]NDC210JCGGEK4D$L*1LZY"75?1W8?
MXL7]]?B*Q2PNKF[#QQY^+3X4,(O3_)X=M=Y[WS7OKO/>^:]]6%K<V=GB&]78
MVXZ7IIPFQZ&[`IM9Y'+G6YQWSC^W6YQWSC^W6YQWSC^W0BQ[+9WCG+7RJLH<
M2BMKQCF)7^EGSZJW6.@#PW]KA6ZQW/+>/[=;G'=?&/[=1PX[FGC'`74G;X>F
MKNU2_OU)($4$0WS`\QQUZZDQ9;;:APZ)8XUT#Y9L:?$KZ0YFZD'8&(^%0XKB
M$/D7+$=3':^-1SV>*>(N8A!=/Y,J\,_O>FL+2XL9,2B&2RI'F,^>7`^BNEVV
M)*(KT""=>$JCRC]ZKFRN+4AN,?T7&H/56(8BUY':*9"S11@/VMZ.YBK9VN&C
M9RRC/Y=V``S0@\"Z_$5C<\T-XJQ2NB[M.?972[GE.Y]9KI=UYY_:-=+NO//[
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M,0+'%%V@"R9`9]E=#-]@M@D+('1FSS(K]GKOZ\?M#]:_9Z[^O'[0_6OV>N_K
MQ^T/UH?)Z\VMG>1>T*M83:V.*02LNT,@-:Y]G<M+VXLI`\#Y=:_1/811.'8R
M.`L;[_UN:B:ZP.[.>3`^"5SS5UIK?"<2S>"XZ%=/KNW_`(?;3X#=C^')%*.L
M./UH8!*N72;F*!>?A`GW4+G"\'5A9CI5SED';R5K!)=ZV)22R`-)%Q/&CH6]
M)K*HI9('$D3%'',4M[9XFHBQ!1#.!DLJC+/JVOSKY0((8,,A#A]W$=0>6F7=
MX<\LN=-=0G5KA<^&K"A-%RD73M'<+HH)+@`<=>%=)A7^>H!^\/UKI*H@_>-A
M#P\+3U:UTQ/M7'[_`/O6^8#,RL`.>T:6<L,UF+#K#5TT#,=+\(??X>^A.&#A
M9\\]6R;XT)X1_.3VA0EBT\8NO#45^5;^#3QR]GA"C<QMQN%8]K`_G0=&&C`A
M>)SX4+Z-?!Z2!_W:?&MZ&7:WFT!Q.>GXT+NV8Z3+^.E*Q&;*Y&T.1Y4/[&TQ
M/A,6RX9]T\#5]!"H@RB0;4JYG9%7\02U8PQJK#9UX<Q6WB&0RAC'#Z52*Y@O
M-ZOA;Y=,].-)%.%`Z%`XRTS(JXCE%Q:!;>.1@ASC)R0:\JO%N%A):QB0`KFR
MD$J,^(%7EQGN+:(/)&-DRF,;1RY#U\ZLIQ!<M;"*2*";6(N,LFYK5LKF6\V;
M:*4;SB2!36T_[S(8DMU,9&2'RJLXINC0_N<+^#H2=?75SM1=$WL"Q@2#R-0*
M<A59L\E`K#8HY+)6,0S\,@D=IK#8(3$Y,:G*1N6HISLQ3C54-P`VSR3/6DM[
M3=KL1(4RTT%2);>-@AF:/PN'\O/J!ZJ:*6.(AK&*1`-2I`.76!U^BK-HWMXV
MB#!,M-KB.RO=_P`!XTDR#C/9.8](]%211RKL2#->K,CAZ"*_*GL[>171DS60
M[3>$XU':&!'JKO99_4?_`,T_^I2VENAC(0YQ#)27<D#UL<_7G4L23(8Y!FAY
M9D?#(U!;0VV>Y38VN/A,W^8FI8(IE"RKM!2&&I&1'#4$&HX(H=O=KL[9S;4G
M,^LFF174HPS4Z?\`V5##+,#((X`_ZT_^I2V=ND9A"$QGD7=O>S%AZC7>^URV
M=ALARWLO]=*JHH11D@TRJ.*.$$1KL@G,\>/KH6\*AP$TDU;B<_Q/PKO?:@;(
M1@.K>2_UUT:#=[G=^+ZM<_QSVO?7>^URV=ELO\67^ND58U"(,E'`5P_Y(/_$
M`$@0``(!`@(&!`L$!P4)``````$"`P01`!(%$R$B,4$4,C11!A`S0E)A<8&1
MD]$C0)2A("1R=**STD-B8['4%24P4%2"DL'A_]H`"`$!``8_`OO)>1TC0<6=
M@JCWMLQ>&6.4=\;JX^*G[Q8GV>)*S4=(:680(E\N\1>Y/NQ#&VB]DDB(3K1L
MSL%OB.GHJ:>HZ6Z,P@1F957>%\O`;<01SJR5$K&656O<7ZH(/"P^\/3Q5$M)
M4KOP31.4(<<B1YIPU%IO(\M.;0U*-FUT?]X]XQ(UNSR++[.6*>5^I'+%(UN)
M5&#$?#$.C*6FG7/&<CL.&0<_5B6JBII*N8$)#3Q"[/(W5OW+B.;2D*T]5)O&
M!?[)>2GU_>)::F,]/4-'GI:J,!HV<>8WJQ6:)\(KUL%1"T>Q0KAQ[.5QB:.(
M6C5R(P>(7UXJ-)U,3R2Y=72A1U;]<G&OF@$`+?8@]9AZ5C]XDM$9MT_9*;%Q
MW`\CAYXI)'IKY^B3;TM+[&Y@8Z4L,>=#9GV<>^V#*SRO5ROY*(C*N(Z"FCME
M(3O-^9:W+$72&EK93'ESJ<L%,G=EY^-F;8J@L3W`"YQK:=PZ7*W'>NP_H0QS
MRA'G.6('SCAH)ZI8Y8^LIY7QVV/';8\=MCQVV/$4[U*B*87C;TL=M3';8\=M
MCQVV/"R1.LB-M5U-P1[<9I9$C7O=@H_/!4UT5QZ)N/B,6CK8+\-YPOPOBX((
M/`C:#B,U4JPB0Y5+<+XS*5DC<<19E8'$\,,<=+(P++,B6LW]ZW$82DH]YUJK
M/(.H$1MYB>XC&LCIXDE(WI$0!B>>)HX)`[T[9)AZ+=WCJOW>;^6V#3U$^KE6
M>8E;7\_':OX3CM7\)QVK^$XT)T276ZNI%]EK7.S&E_\`:@C*E8LF=<V]E'_K
M'DZ?Y./)T_R<>3I_DX\G3_)QHH1:LT4!.M3)9`.6S'DZ?Y..I3?*&/)T_P`G
M$GV4)W2,J0[Q-MF7&[$[35E6ZZ-IGN6R'@;>ACI.G:F69Y-[HB,5BC[ALP%2
M@I[#THU8_F,?:442^N(:L^[+CI=#/)6:/3;/2RG,Z)_AGU8T!4"S4]35*KKW
M`VSH?6,&HT2S5=#UGT?(;LB_X)P5C;5S@6FI9=V5#P893Q&*]EA1!-5,\6S>
MU9]?+;XO"&W_`%B7^#>.L_=:C^4^-=/30R2=*J!F=`QV2'F<=BI_E+],=BI_
ME+],=BI_E+],>#0IH8X=95V;(H6^]ZL>$451%',L<<)0.H;*<J]^.Q4_RE^F
M.Q4_RE^F.Q4_RE^F.Q4_RE^F/!^".FB6.9WUB!%"M8<Q;'8J;Y2_3'3]"ZNE
MK4.;4NH-/-ZB.1P-&>$&BH-%:1&Z&DA7HU0>11[<3@.E'3=X(C0CW;,:!DJ<
MJ4+(T4?)%G\WU#;^A62SLJ1+3RYF?J]0V'QQX/NUUCFTW-JE/)-9L(]1PO[(
M_P`L=)IW-!I%-L=5!NW/=(!UA?":/\*(<@+9(-+1`FGF[C)Z)PLD3K)&PNKH
M;J1[<>%(/FU\8_)O'6_NE1_)?%F5E/2JG8P*GRA[_P!#P8*H[`5>]E4D+O<R
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M>6FU]9$VKF4JRG*UQM&VWC-^%MM^%L66:G3U!T`O\<;)XC;N=?KXB3(@"]8E
M@`OM[L`M+3L5VJ2Z&WLP'D--O[0[:O?]A/'`%Z.YX>2VX+&&`*-I)1``/;;`
M:..G=3P951A\0,%3T,$<0=5<>['V;4[:GT"AU8]W5QVF'YJ?7`M-&;[!9UVG
MN&WQ;T\-F[W6QQ]G+3+?T'07^&#E=&"\;,#;V]V-]Z5B.9R'\\:R,PK%QSKD
M"?$8L*F+_P`Q;XX!95>VU20#;UC]$E55<W6L`+^VWCL>&*8B"+;5QWW!MXWP
MQ@AC20M';*H6^\-A(Y8'ZO3\O[7U8K]<BZTU45U!NM\W?W83_=U!U5YCNQH]
M5I*>600-^KE@L2[WFG!UFBZ2G3.EYX75Y(MX;R@#%-HZ(5$\.6-ZMX4SOJ_-
M4_M<\-1K#40T4^VEZ1&4R2<XUOWG%?DHJ>H_6=KRL`1ZMHQ55;PPT<8I7350
M,&$NP[SVYXI2FCZ)UU0L[D9F'>WKQHYYH8:>U4H;5=07.R^'8D!0C$L3LM;C
MA&DA1S]ME9U!W<S<+\L2DP1$BJDL2@V8JPI*0MI)$G9-F6'-O>P6PN2G@,=M
MTY5.9>^_/%524U4\*](7B+TZR\=4I]'#"71=%)$J'.Z.J-D`ZRCTL0-!G$>6
MRB3:XMR)/'_@IK%S9'#KM868<#ND7QDE7,NPVS,O#AU2/%+&\5UF8-(-9*N9
MAP-U<%?=;'DI_P`?7_ZG$)2,W@7+$S2S.RJ=MKO(<W_=?!BE7,C<1=A^:D'#
M]'CR9]K7>1R??([85)TSA6#KO.I5AP(9&!'QP^I3)G.9]YVN>_?8X:-Q=&&5
MAM&P^S%EBF`[A75X'N'2=F&IQ$QA;:5DFGE-^\/)(67W$8"F*4J.1JZPCWWJ
M-H]N!&JA4`RA1L`&"D*9%+%R,S-O'B=XG$RB(6G):4$LP<GCUF-O=;!`BE`/
M(5=8![AK]GNQT;4KJ3YN]?VY[YLWKO?&75RV'+IE;_J-N`B*%518`<O^2O_$
M`"@0`0`"`@(!`P0"`P$```````$`$2$Q05%A$'&!($"1H;'P4-'Q,/_:``@!
M`0`!/R'[6Y9+]/B!BV6P/S'!>TG[TJ!^W=2P`%P%JZZ)XC80-U6O`17#+UGZ
M@NX]^,I0YI,/B4%31&[WAL^W9SSP=N.[*&"2.:WN4\1?,Q^>%O"[#QN:?S,J
M;7=&:CC!*=@X\H_/B.#FG)MEUX>:'-\?MF8R6CMQ*Y-]QW8X._.(N5_%TQ5#
M0S&D:T2T>51Z$I*J*LZ$K45Y)'A^^/#]NZC7@[,PI=L)@`,N1S@R\42V8=Y#
MTY*K<J=DEL+39U,EMAIUZ!S*K>8RBK+?JO5(O)DR?`,\,#U=1\,N7+G)4VVN
MB..@-ZJR_CZ$1/@I;3TM'6)P:_5F$0,FG1UEX@8#H3W()\%6VWED9-PM/Q;(
MJTQP;7W<P*9K6`X1-D%T(40[>('PX+Y*,)#Q<0I94;!=RM:J:QW$4'$V1<!!
M2O>8/P8=M=+\/T3@_P!A7!557T&,8_!;%;VHIFAC^@?0F,>+]/\`S%BIUP/2
MOH/_`%>;\>@^EV940*&[BT>'PKG>0%5*[G7+YH6^R,6C1^_-!41>.3V@4Q,Y
M[]:<S=#J9*'!P70:R?OEI`>7''B696U0<@V%D4TB@:5G<+<0(WB%?,]1V>F_
M$K*TAM`&#Z#0H426+#HPNF8($D0@*`Z^@4:-?Q<0T.@AP592MDK59,3EJHS:
M*Q"-C"C13J;P\RXC^FQ5A(*:?((%$.P=0[[T_P"O'HQ.,:`LGDY:$)]R'2GO
M1:E_[ND#FG:0R50M+7,5GOHUDAF*SW!GJ,M%B!G`-#X]<-0*T@%JX`#;*?FV
M^*F@8AZVJAH\IDE?./VU^TV2.J^ATZ=.WAOP$4*_T)5_VQ@3]'1A&P9L`>ED
M>-C3YE2;]>*8<3H#4)6ZYNK%R\@X2J+L60^>]\S,"'X3V$PX%,5L`X7FX!M4
M%RX>.[9_2])4J;2#\5Y\Q4NKS=+E)IH125R]@@!35GK1@47L&;OBH55A=G'.
M*9N7&K+;J\%UAGT:7M(PZ&N7O%\S`KS2XB[3NN`Q?`ZF;(M"[KH.6'26B`Y5
M0)L"L=KI`Q.*%4B=/"9^H7[E/3^)@PO4!N5\H]@R?$6OC<IL$:*Z-.%R7B71
M<:2R=4]PE;6A5]\<0V</XQE35+X3VXOW`5VM#2GQ:IWT0"X5_DA@^A=8A3C.
M:,OJ@@"A$=(X1\5`<T5!JX&C(PW4.@$`.4X#AP9*?B8Z?!(@PQU3<VI3?Q#'
MDN<3-%?J)C$32;A[<$(3.KA3.=84YPF!=QF"`<*PJG`3$L-+P-M0`HQZ$SSE
MU9R(4L$,6R40C_``6Y/4R7K9%,6$#&-0-$H%,5'>:`IJW2*JMC;<#=&29N)(
M8-^$X"W)-X#JBTQBF2N8-12XZ#84[AK_`,`16)_B\2]-DP[[R`Q5NPG<`H&*
MH/C46&,R$6%4/>*\`E50.#JL9;%Y@A9.Y\I3#JV^TV8!GIF>=XJZ:S@'0AZ!
M'T3:RD8'DIE":#74L@W9L*DM"8Z2&T<4#!T%1[1YBX3&E^.YET@B8LX'P5B<
M`(8C5%>)M%&"Y1Q?5U.:FY^:OXFXAN`$,\!4^*2I=LM8]_[VN+%OJ2&.'@\-
MD)\[3`_NV57^$/_:``P#`0`"$`,0```0``````````F#NH``````````"POC
M```````````8L`*``````````#==:```````````<9I@%428DF`AC\<%DI`%
M9(,D(HY)#9+70$BM+1)_,N07"$<`#VP[2F6W.YZ@]0#;FDW89D3ME"$(`_(/
M-=MQ?OM@@```SO<V[&T$>W'``````````````````/_$`"D0`0$``@("`00"
M`@(#``````$1`"$Q05%A@1!QD:%`P;'P4/$PT>'_V@`(`0$``3\0_B+/4R#U
M^>LAW_?&`XO&N'64_'ZF1))N69MM>*,\38PE>@PO\?1?C-Q/A'W#)?C.)$2I
MJ<>^L!S3@!ZM0+!ZG)CU#_[IA/.\-IR#;S@B9L4LTJL'G^.-?;XXXS3!P(">
M%,C<&Y'4W%3%.GL57*'L,[)*3<[91A^>_@`1]\+`I;I\V":KHN/@]PNTM$7K
M,Y?FUI/*(1;X_C:'V_K%!*!5``<U=`'>/S=S;$-"I#P3`9;-4BE-"MZ]XS5M
M*@_;I,6AAQL.BZPYN(O8LB%@,@'.L!'X_P`<?QM/"?UUB.2\;VE`@@W*5<+&
M+8*52--X4]-`B6-!P!.5R!PQ)8$KKA&D0@&FW2@MZQ_:(,8TLCI!?J35NM"2
M^E/C*>LI:)B]"81SJ?-F1YR/.&\;JD,'>;K.8=RT/.U4.?[3G^TY_M.%W0>3
M`A>;XSH<XZK7M1R;]RY@>;DO1XO6=7^34PMI8(QJ!1@%VX3ZI/C2J9)]\-,4
M2M'O'OE1$FD8DSK)`Y#4<`'\'"5_<DY,GL,H#$Q.45A*;<TN'Z!U10Y)'T([
M+G67N]8^`]DYMC!SVF+9("25$Y1S7W$D=+[9^#ZR:M&GT:9@T'H(7H)9]\#X
M,/A_7USD=%=R`Z'P.'ILC"M8,YEUO)>OUZ^,_P"C_P#K/^C]?&,VTXT;ODP9
MQZ\2A8E>"XT>4`XFO$G.$=:NDD]6GXQ$\/H<?&"/[E_H8)&SCQDH\B#V\L1T
M*3`H#1T(V:1ADU+EM$&:.VX^^<DU1`WT208Z.N,BJ,3.R@#K>F'"O(JM8<(Q
MR3WC7<K,U$%:7H3TR`Y`7DB`'4/&&/2]PH(X(]:R#P'ZXXR(T!'/#IU]6!TG
M32*B?C'8-45JI8!YP\#^B?;ZK%A+H9*H$U&^<5&?/$Q14FISDO7^KZ)DNF>K
MC#;M.$YE5BGP$@!(:1XR:FC;IB!-9!;H/86[4`'+<S3)K0B]9%C(>)BEQCQW
M8C(*)3$'B#;"00AZ8A0(@$&B)I1S$^@#U-ET$UBZAQY?NJX#RF.L"]R1][+I
MC'GW^WLQ;4N>6KGL!Y<W)^5#8`V7*0<KEVUP,R(V)KDX=X/OVZ5U_'U8B*N4
M`!48`<N&WX"T33*-C,$.S]<9,F'H^$3NB!Y1DPEX#$$8M'3D?5^GZR9,(5BA
MHG)>KK!68PU(*3;TP+ZD]=<X`?'XS69E(+`'BH2J<ZQ7W%)S.@$+>$/6`Y7K
MIH&J0V(:1PB!5\2DD@`IQD)'H(JM"E(UFK0P+1$`5B[LPA6I?;>!!"@C#$AJ
M12.GO%2VK<)X8>]))7V8CWK]36)#ZU@S;$""*CSC)BC2$PPK73KCFZ@E$,<`
M!4^K2FSH`%XQNMU,F27.J+(>;O"-(:.T)P"@+W@CPB:D;SQ^L!=S4XA$1X(<
M=K-#)WE?L3%$H59[&T=@LXP0\!/)T<I'HQ<61]%3`3M9ENI;ZT=<$Z<MH(A#
M56WZ0P.`6A"'DNGEP*$+E""&N3>.*H0L*^BA5Z5P`M`VV``*J]`88$-(7CBP
M@KG8W+A^Z4O((UZN`:%)3:T(@%W.,0'&')=*:(/.]8N0#2AIE:ZVX9IHX)H%
M&SHWO(ZB#2A1#+SHP@`0/'6?[^,D^/ZQ$\_CIZF:,K!D!0EO;7ZG(&ZA(#RD
MB8VMW=&U@LY&V8A53IAF'@YO&`D`922V.ML!88#M3I]M.>\[KS#IRPN.RF>[
M1"U:[1HUA&D<Z\$I"C"\<078CX\AH@A=#O"1.06:9)93>H86E(/O/J0M)MSA
M%U^B#(`UT=[QB#)1I"%&%'O.@HO`2<4[>,3VBBT:9R^;K`=P37-L"=DGG`UX
MFZ^I'2><48"1'SOAO0.%4-@8*+'=%VW(^))666\X.A<0LZ%U*%A28D3#1L;@
MUZ0"YF:CU_7_`(._/7%GG`Y3L<%2;:KB)$,T9NF#`@`KH`#;T!EOCCX1);(+
MR8$@`(("`!@/$P^QO:FKD[!<"&>F;V=P<`=/&#!&YC,M#F&.C-6)[;=$!=@!
M[&8*F+"@T#1V!Y=X4A*+(V^TE0=.'=WE+J!KET#"R+^&D!LD=.)ML?:$6&HY
MKA)DM=FZ!T39WSM;<Y.%4$.[P&@'09#-U,"*0FL(<@3->[AR.!8^(F:F!O*C
ML:1">N;`S54"I6NG>&DFL"R1Z!P*JK#:*]K@!`@?/^?^$/_$`"D0`0`"`@$#
M`@<!``,```````$`$2$Q05%A<8&1$*&QP='P\4`@4.'_V@`(`0,``3\0_P`F
MO2.(XKCI++KIC4JO2'V'60'NT36"=!^B_P"?!O!*Y$O5L"EEHGRF/(AIGSQ,
M(M'&,C*`-!9KYRHK&A&E%&'_`#ICQ,3G5B"^]?N("63,Y+Q^4HQL9*W0^T:N
MXA[!SB6^T6=B&G\RS`C)Y:OH=>D,JRSI=/\`,$<'`>TQSJZ&C8.NA&(PQ3&1
M0`%CK7M+HJ^)A>%@",5!7%[*-5S.HW]@=3)YJ75'3G7I_FOV3<#0()<(/#TF
M<%6?:XKO*2]0(0CB*A=FJ*>;@4`\`%KUIS`HLR,M:5US7!^MO1=95X&7XJ+;
M)T"U]`@S.FW=4P'T:E=Y7>&ZJGJZC;3+C)99/XS/XS/XS&T4'*K>(3([2;].
M(M8.QE'%Z,/!=F%PKX/$&HMFA.*E>7,,7Y8SZ=+[(&,X!I\"+E[8]4B)Z)%`
M3B6WCV^4KHY,4IW/K&'WH99;P:TY0EP,I5)X*0P.[B1(`#,%*IG,T&26WZ?$
MDR@4ZBBO74/$J6@Q;IY)B5\R?HN?HN,L#:;/I<%0WHZ51?$[+Z)_%3^*A<,:
M67`>TNG#170ZF((3#PH=^>L-.7I26B!#2)2`2:4NZQGCV@"BG>-4="X70]%#
MOLOC$&!E?DX,M*SHY=*JJKM"[.\+0[N/""RJFRGG/:-!5M%TYADQ$CC=9`>)
M78N*<"B^,G'%0":`3?+YA`R`[<[]_BFZ)#N))1VN+'>%!BKLG\B?R(PQ@X*Y
MF;:F#[2KL=I_`E'X)BQJW@A+#=6.);X,ZKF$$C(N8I]+E=AH9"L8ZH`BSI0K
M[QPRS*L*X8.W'V^%N!BXBI:]RFOM*B4J^%PT<8^T.HO3PQ4C8,M6+=U"#[,-
MW<_08OXH!A">J"`?%)X7'%=OB$0V.E,/:#7@%#Q4IX*_;4_4OM/U+[1V0?\`
MEQ!-BAL,5WYE;]1Z05IUVBL-,CRN$>T*99-V2Z%=L9Z1):#*J3BH$*N`;>W4
M$V<X6^A'WI`%/J1O@3D7B?+C,R!!]G7VG@8,>D,1@?>$_:\Q76E7<I;FNQBN
MD80PH\'XJ`V`,K@#F^@$4`+D5YZ=T+UFNGA-,$X@B=`20N!5P]F(Y`-BX?GB
M88/DP3I;D.I"LZ0,W:BXG(JU``<JX`E?P)[(2R'0KTC<NB7A\RSXPNZ;;8=V
M#9[/[L$IRP9G@*<O8EA>:HSV_$<*P4HB#7+DN&`OFNMZ8=RV/H$PZ\'K$D+N
MS;,=7)'(`+4P&U&,=X\E'`U/KJ990[?A@:''Q&O!+6L5;163XH(H$2D=5ILZ
M3""W`HC>@W*+8+3@HLCZ@`I9+*,UVZ?"V!0,!;:1JC9S!J7D)=M*Q"X6E)K:
M47WN(;00'C:'.O1*DYJ`KTKRZ>T)DA9`!NB/F'=PBI5*D`>T+C6&/*GQ;YFL
M80;+>+FCNQ[A5L%,"WL<^T-&`#V12S3Q4L6I22M=;&JXB6J_6LPZ:*F-V+$L
MK*J>YFR]03:#9J_)JY9"76D70:%I;<&($"[5LMSCB=,51S_SUZ0(40SBC3D:
MZ..TP*2/)*S0X24`&C0\1^`!"]!PAT0ZD`NBLKL&"C3TJ#O.>8RBL]],:G=!
M:R179)ECANJ:UE8'00F!?X7;L`*O5T\C4N$`U8*&B8=E\YEBP@M,.$L1/1)3
MG-`(>`H>"B%%A;974]#&85DMV8OO:L[K.T)&2AT!BI;MDLA;=#P4=H45:$--
MM?2#B"%R70P\!4=BCM/)*MWK_068TL(`.$T/([-]X;(=!HKY^\#P_>__`$C_
MQ``I$`$``@("`@$#!`,!`0`````!$2$`,4%187&!$*'P0)&QP2#1\5#A_]H`
M"`$"``$_$/TFL6G'7X9J..LDOCE^?ZS7B,()>A?@).1%,F2QZ!^GCJHR1F;"
MPNNWK"4;YWNLE^90)H0U\Y&=PWM1]L,T+`9*FD(K!*+`(>3)N_TZ5&38"1<G
M5#I,4A)0P1:>%QQDP41IYB/<=9$"*G4+&OG%%$P=C`]]F1%*NUMP/.+4@!<N
M4\?ID4@?;$$%'GBLUR>@D33MOWDJUBCD$N8B83+%A+5O&\65(5D'?D/6\'^&
M8.Y*8^,"3,'\U^F0B]?G6/3((BE(U+3&%9,[7K"[2)(Q+07K)`B,#%U3/9@;
MI%N$08ZK-TH,@.NIPK0)#!J@""?J9L,':L!\KA:B$)Y$F$@63SE^,OQEF<@X
M=X*'V0W#'VC7^'_X,!+`J1CG_@FOEAN=ZLR/CR'K,;(G$QXZQFU="%:A'^<C
M1P/^D,8-:X*OY8-(QR#]C&6L]:0B.(><M*F1N'%=L9032(CAD3*3HJ[3&J:(
M]Y`9(`85L+"8ZQ$FK`$'B?6'.!-V-L<?6D51#DDTH;JC?SDEI*-,_&,_&,`!
M"!+.C9U&`U`L=E_?T'_T>?\`1XB2=@>)5X@6M5^%NYRP-?Q>>L2V;HE]L`(+
M!K^!DN60BHFQ8C'&@AIVWGG*<E31TKX>+Q,(Z#^R,CPMM0]6:^<6*9FB,FW$
MJO`37+24H#E$(X`0$0GAZXZ"R::&5)IUDEZI4`8\*#><CJ#7C+Z/C1)-OKH(
M%])/VPF+H$14XPZ@WE^`?WGX!_>3:629E'$ZP.XI4:7760^#\-Y^(?WD/!'X
M;P<!7WZP?T!DQVWD`T&A/C"<3Q-'$(\AA>(S,.1@90.?'.2950DWR3B9(KAM
M2#RZ<)%DCA.D^C=%#;E30$<0R^()7"-!I^37XPS`B2'B6,GMK!-<S;1D"KR`
M<O2!UE6``1([.,,YM)^?J)%(-CHY'P9!HQB>!.L):(CC(.L@ZQ^`"`3;4[Q/
MU0F85X6MY'X?IET>.'#!);T>\C<J`$8ZO$0"L"8-280FJ;C$"<45'G01P:,"
M$D'H5%^G%`U2'(:7N28QT(`@B1L-0OO%09:%']\%+N\LY@6XQ2%8B1(4#K9'
MO%7ARD)N`G@H]&#A*6'MC-(G6O&.K61$:X>SPXT)@X((`[6D[R';@,EM`J,'
M/U4"T=D1',\1N<1F17I4$+,^,1,NFOO7@G'&+"^$@%P*M/AP(D>A(CYT_?".
M"TPB.Z!ZDG(T(SH;^(PJ$*5`0<S.#W72DKR,8(02W6Q0)I'F,/;N1:[@L%<X
M(`X%/7\XH@\@A<]%V^#)CF#;U@2@%WLDJ1GA_;$X`L2IZF5XTZL#([ZC$]=H
M(AZD@8),&FV(\E(PQKJ:R?>LBB(H2'PC9&`"N/JE@%O/48O!T298.KX]?4$"
M20R.HC630@^`1G08N^(`/V'_`-PH8+3>()^<"PE")2TQZ-F0'52<X'$H7LID
M2>N,%KE"DT`1/>,`?4:=H:IB+4R<P:'5Z[C'PQ%4R")"/O!(G4K(&V(C`5:,
M!+<>W>!G(D&1-2F@Q"A%5U13/JL2M<`M50MGC&\D"2P)`J.L>?6N0T!6B-XV
MBZ:D]JHS[<H4QF+]B2Y-8\>[%`2P)I=L%F8"4Q2IN#"2))''^>OC"8F!2D:&
MQKK7C)V2A[));*3O"@"C3&OB@,;AI#I!XRF(P(@*OBN&"6D8F%9;NLHAR>!L
MM_L.6THLAC5KKB,W+'#E2!$3J8>1R,5K4@@="NHR)D%$I20DH2N1G!QP@`@.
M@*XQ(!5<FH^)#`1+U)3Y%R>&3!+E@:`Z[_O)PT%*E;;+\%8<V5!03MA(_9XP
H\,2(/04/!!D=3V?)S/-O.<%CB/XYQXUD("P$Z]LK[6<#0J/_`!/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
